Pyxis Oncology (PYXS) Notes Payables (2021)
Pyxis Oncology (PYXS) posted quarterly Notes Payables of $9.1 million for Q3 2021.
Pyxis Oncology (PYXS) Notes Payables (2021) Analysis & Trends
Pyxis Oncology (PYXS) has reported Notes Payables for 1 consecutive years, with $9.1 million the latest figure, recorded in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - |
| 10 | Pyxis Oncology | 200.93 Mn | 167.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 9.12 Mn |